C12Y 116/01
Oxidoreductases oxidizing metal ions: with nad+ or nadp+ as acceptor
Official title: with NAD+ or NADP+ as acceptor (1.16.1)
C12Y116/01 (Oxidoreductases oxidizing metal ions: with nad+ or nadp+ as acceptor) appears on 42 US grants and 54 published applications in this corpus.
Search patents in C12Y- Granted patents
- 42
- Published applications
- 54
- Assignees
- 20
- Inventors
- 62
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 2 |
| 2014 | 1 | 0 |
| 2015 | 1 | 1 |
| 2016 | 1 | 3 |
| 2017 | 1 | 12 |
| 2018 | 8 | 2 |
| 2019 | 6 | 4 |
| 2020 | 2 | 2 |
| 2021 | 2 | 6 |
| 2022 | 4 | 14 |
| 2023 | 2 | 3 |
| 2024 | 3 | 0 |
| 2025 | 7 | 4 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 116/01001Mercury reductase6
- C12Y 116/01002Diferric-transferrin reductase0
- C12Y 116/01003Aquacobalamin reductase0
- C12Y 116/01004Cobalamin reductase0
- C12Y 116/01005Aquacobalamin reductase0
- C12Y 116/01006Cyanocobalamin reductase0
- C12Y 116/01007Ferric-chelate reductase0
- C12Y 116/01008[methionine synthase] reductase0
All 9 subgroupsShow fewer
Recent patents
- Using synthetic lixiviant biology for the recovery of precious and toxic metals from anthropogenic sources24 Mar 2026US 12,584,191 B2National University of Singapore
- Method, system, and composition of matter for reducing toxic mercury in wastewater effluent27 May 2025US 12,312,267 B2i 2 Air Fluid Innovation, Inc.
- Peptides and combination of peptides for use in immunotherapy against various cancers18 Feb 2025US 12,226,467 B2Immatics Biotechnologies GmbH
- Peptides and combination of peptides for use in immunotherapy against various cancers14 Jan 2025US 12,193,997 B2Immatics Biotechnologies GmbH
- Peptides and combination of peptides for use in immunotherapy against various cancers14 Jan 2025US 12,193,998 B2Immatics Biotechnologies GmbH
- Sequence for protein decay25 Sep 2025US 2025/0297290 A1
- Fungus and microbial agent for treating mercury contamination, use thereof, mercury removal method, and method for identifying fungus capable of treating mercury contamination21 Aug 2025US 2025/0263650 A1Zhejiang University
- Transgenic animals for mercury bioremediation7 Aug 2025US 2025/0248378 A1Macquarie University
- Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same27 Mar 2025US 2025/0101399 A1Inovio Pharmaceuticals, Inc.
- Novel peptides and combination of peptides for use in immunotherapy against various cancers26 Oct 2023US 2023/0338489 A1Immatics Biotechnologies GmbH
Most cited
By later US patents
- Peptides and combination of peptides for use in immunotherapy against various cancers16US 10,058,598 B2Immatics Biotechnologies GmbH · 2018
- Peptides and combination of peptides for use in immunotherapy against various cancers16US 10,098,938 B2Immatics Biotechnologies GmbH · 2018
- Peptides and combination of peptides for use in immunotherapy against various cancers16US 10,179,165 B2Immatics Biotechnologies GmbH · 2019
- Peptides and combination of peptides for use in immunotherapy against various cancers14US 10,314,896 B2Immatics Biotechnologies GmbH · 2019
- Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same10US 8,927,692 B2Inovio Pharmaceuticals, Inc. · 2015